Oyster Point Pharma Inc

+0.53 (+5.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)291.48M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.5 Million
Adjusted EPS-$1.38
See more estimates
10-Day MA$10.79
50-Day MA$11.87
200-Day MA$16.24
See more pivots

Oyster Point Pharma Inc Stock, NASDAQ:OYST

202 Carnegie Center, Suite 109, Princeton, New Jersey 08540
United States of America
Phone: +1.609.382.9032
Number of Employees: 62


Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.